Literature DB >> 18043987

Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma.

S L Ong1, G Garcea, S C Thomasset, C D Mann, C P Neal, M Abu Amara, A R Dennison, D P Berry.   

Abstract

Despite extensive preoperative staging, a significant number of pancreatic cancers are unresectable at surgical exploration. Patients undergoing pancreatic exploration with a view to resection were studied and comparisons are then made between those undergoing resection and a bypass procedure to identify surrogate markers of unresectability. One hundred thirteen consecutive patients underwent pancreatic exploration for head-of-pancreas (HOP) adenocarcinoma with curative intent. Fifty-five underwent pancreaticoduodenectomy and 58 underwent a bypass procedure. Student's t test, receiver operator characteristics (ROC) and logistic regression were used to compare the predictive value of preoperative patient variables collected retrospectively. The bypass group had a significantly higher median CA19.9 than the resection group (P = 0.003). Platelet count and neutrophil-lymphocyte ratio (NLR) were also significantly different (P = 0.013 and P = 0.026, respectively). ROC analysis indicated that age < or =65, platelet count >297 x 10(9)/l, CA19.9 < or =473 Ku/l, and CA19.9-bilirubin ratio were predictive variables for resectable disease. NLR and CA19.9-bilirubin ratio had specificity values of 92.9 and 97.0%, respectively. From logistic regression, a raised CA19.9 was found to be an independent risk factor for unresectable disease (P = 0.031). A significant proportion of patients with HOP adenocarcinoma are understaged preoperatively. Preoperative serology including platelet count, NLR, CA19.9, and CA19.9-bilirubin ratio may be used as additional discriminators of resectability particularly for high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18043987     DOI: 10.1007/s11605-007-0422-6

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  25 in total

1.  Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas.

Authors:  Kimberly M Brown; Christinnah Domin; Gerard V Aranha; Sherri Yong; Margo Shoup
Journal:  Am J Surg       Date:  2005-03       Impact factor: 2.565

2.  Impact of endoscopic ultrasonography (EUS) on surgical decision-making in upper gastrointestinal tract cancer: an international multicenter study.

Authors:  M B Mortensen; B Edwin; M Hünerbein; B Liedman; H O Nielsen; C Hovendal
Journal:  Surg Endosc       Date:  2006-12-16       Impact factor: 4.584

3.  Post-operative neutrophil-lymphocyte ratio predicts complications following colorectal surgery.

Authors:  Emily J Cook; Stewart R Walsh; Naheed Farooq; Justin C Alberts; Timothy A Justin; Neil J Keeling
Journal:  Int J Surg       Date:  2006-06-27       Impact factor: 6.071

Review 4.  Computed tomography, endoscopic, laparoscopic, and intra-operative sonography for assessing resectability of pancreatic cancer.

Authors:  Eliza E Long; Jacques Van Dam; Stefanie Weinstein; Brooke Jeffrey; Terry Desser; Jeffrey A Norton
Journal:  Surg Oncol       Date:  2005-08       Impact factor: 3.279

5.  Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.

Authors:  D V Mann; R Edwards; S Ho; W Y Lau; G Glazer
Journal:  Eur J Surg Oncol       Date:  2000-08       Impact factor: 4.424

6.  Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography.

Authors:  Antonio Soriano; Antoni Castells; Carmen Ayuso; Juan Ramón Ayuso; Maria Teresa de Caralt; Maria Angels Ginès; Maria Isabel Real; Rosa Gilabert; Llorenç Quintó; Antoni Trilla; Faust Feu; Xavier Montanyà; Laureano Fernández-Cruz; Salvador Navarro
Journal:  Am J Gastroenterol       Date:  2004-03       Impact factor: 10.864

Review 7.  Pancreatic cancer.

Authors:  Donghui Li; Keping Xie; Robert Wolff; James L Abbruzzese
Journal:  Lancet       Date:  2004-03-27       Impact factor: 79.321

Review 8.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

9.  Patient with markedly elevated CA 19-9 not associated with malignancy.

Authors:  Douglas Lowe; Jeffrey Lee; Robert Schade; Ayaz Chaudhary
Journal:  South Med J       Date:  2006-03       Impact factor: 0.954

10.  Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas.

Authors:  Thomas Zacharias; Daniel Jaeck; Elie Oussoultzoglou; Agnes Neuville; Philippe Bachellier
Journal:  J Gastrointest Surg       Date:  2007-03       Impact factor: 3.267

View more
  16 in total

Review 1.  Indications for staging laparoscopy in pancreatic cancer.

Authors:  Antonella De Rosa; Iain C Cameron; Dhanwant Gomez
Journal:  HPB (Oxford)       Date:  2015-11-18       Impact factor: 3.647

2.  Ten-year experience in the management of gallbladder cancer from a single hepatobiliary and pancreatic centre with review of the literature.

Authors:  Seok L Ong; Giuseppe Garcea; Sarah C Thomasset; Christopher P Neal; David M Lloyd; David P Berry; Ashley R Dennison
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

3.  Failure of normalization of CA19-9 following resection for pancreatic cancer is tantamount to metastatic disease.

Authors:  Sherif R Z Abdel-Misih; Ioannis Hatzaras; Carl Schmidt; Tanios-Bekaii Saab; Dori Klemanski; Peter Muscarella; W Scott Melvin; E Christopher Ellison; Mark Bloomston
Journal:  Ann Surg Oncol       Date:  2010-11-02       Impact factor: 5.344

4.  Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma.

Authors:  G Garcea; N Ladwa; C P Neal; M S Metcalfe; A R Dennison; D P Berry
Journal:  World J Surg       Date:  2011-04       Impact factor: 3.352

5.  CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer.

Authors:  Victor Molina; Laura Visa; Carles Conill; Salvador Navarro; Jose M Escudero; Jose M Auge; Xavier Filella; Miguel A Lopez-Boado; Joana Ferrer; Laureano Fernandez-Cruz; Rafael Molina
Journal:  Tumour Biol       Date:  2011-12-29

6.  Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.

Authors:  Sadaki Asari; Ippei Matsumoto; Hirochika Toyama; Makoto Shinzeki; Tadahiro Goto; Jun Ishida; Tetsuo Ajiki; Takumi Fukumoto; Yonson Ku
Journal:  Surg Today       Date:  2015-06-25       Impact factor: 2.549

Review 7.  Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: a systematic review.

Authors:  Lewis Stevens; Samir Pathak; Quentin M Nunes; Sanjay Pandanaboyana; Christian Macutkiewicz; Neil Smart; Andrew M Smith
Journal:  HPB (Oxford)       Date:  2014-11-27       Impact factor: 3.647

8.  Predictive Value of the Neutrophil/Lymphocyte Ratio in Peritoneal and/or Metastatic Disease at Staging Laparoscopy for Gastric and Esophageal Adenocarcinoma.

Authors:  Tal Grenader; Yevgeni Plotkin; Borzoueh Mohammadi; Khaled Dawas; Majid Hashemi; Muntzer Mughal; John A Bridgewater
Journal:  J Gastrointest Cancer       Date:  2015-09

9.  Very high serum CA 19-9 levels: a contraindication to pancreaticoduodenectomy?

Authors:  O Turrini; C M Schmidt; J Moreno; P Parikh; J M Matos; M G House; N J Zyromski; A Nakeeb; H A Pitt; K D Lillemoe
Journal:  J Gastrointest Surg       Date:  2009-05-21       Impact factor: 3.452

10.  Factors affecting long-term survival after surgical resection of pancreatic ductal adenocarcinoma.

Authors:  Kyoung Won Yoon; Jin Seok Heo; Dong Wook Choi; Seoung Ho Choi
Journal:  J Korean Surg Soc       Date:  2011-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.